Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Benitec Biopharma Ltd ADR (BNTC)

Benitec Biopharma Ltd ADR (BNTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 280,914
  • Shares Outstanding, K 23,216
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,750 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.00
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -2.84
  • Prior Year -2.64
  • Growth Rate Est. (year over year) +62.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.49 +27.50%
on 12/05/24
13.29 -8.95%
on 12/17/24
+2.10 (+21.00%)
since 12/03/24
3-Month
8.49 +42.52%
on 10/04/24
13.29 -8.95%
on 12/17/24
+2.29 (+23.34%)
since 10/03/24
52-Week
2.69 +349.81%
on 01/18/24
13.29 -8.95%
on 12/17/24
+8.80 (+267.17%)
since 01/03/24

Most Recent Stories

More News
Benitec Biopharma Inc. to Participate in Upcoming Investor Conferences in December 2024

Benitec Biopharma will participate in investor conferences on December 4 and December 12, 2024, in New York.Quiver AI SummaryBenitec Biopharma Inc., a biotechnology company based in Hayward, California,...

BNTC : 12.10 (+0.17%)
Benitec Biopharma to Participate in Upcoming Investor Conferences in December

BNTC : 12.10 (+0.17%)
Insider Purchase: Director at $BNTC (BNTC) Buys 12,430 Shares

CAPITAL MANAGEMENT, LLC SUVRETTA, a director at $BNTC ($BNTC), bought 12,430 shares of the company on 11-19-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This...

BNTC : 12.10 (+0.17%)
Benitec Biopharma Reports Positive Interim Clinical Study Results for BB-301 in the Treatment of Oculopharyngeal Muscular Dystrophy

Benitec Biopharma reports promising interim results from BB-301 clinical trials for dysphagia, with ongoing patient enrollment and treatments.Quiver AI SummaryBenitec Biopharma Inc. announced positive...

BNTC : 12.10 (+0.17%)
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

BNTC : 12.10 (+0.17%)
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

BNTC : 12.10 (+0.17%)
Benitec Biopharma Announces Updated Investor Webcast Information

BNTC : 12.10 (+0.17%)
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

BNTC : 12.10 (+0.17%)
Why Novavax Stock Zoomed 13% Higher on Monday

A renewed fight against COVID-19 might be coming.

MRNA : 42.18 (+0.43%)
BNTC : 12.10 (+0.17%)
PFE : 26.59 (-0.08%)
JNJ : 144.19 (+0.12%)
NVAX : 8.85 (+3.27%)
Benitec’s (NASDAQ: BNTC) IND for BB-301 Cleared by FDA: A Milestone for OPMD Treatment

Benitec Biopharma Inc. (NASDAQ: BNTC), a leader in gene therapy, has announced that the U.S. Food and Drug Administration (FDA)

BLT.AX : 0.026 (-3.70%)
BNTC : 12.10 (+0.17%)

Business Summary

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B,...

See More

Key Turning Points

3rd Resistance Point 13.72
2nd Resistance Point 13.15
1st Resistance Point 12.63
Last Price 12.10
1st Support Level 11.54
2nd Support Level 10.97
3rd Support Level 10.45

See More

52-Week High 13.29
Last Price 12.10
Fibonacci 61.8% 9.24
Fibonacci 50% 7.99
Fibonacci 38.2% 6.74
52-Week Low 2.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar